최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.33 no.4, 2023년, pp.290 - 304
박신웅 (차의과학대학교 약학대학) , 장하린 (차의과학대학교 약학대학) , 손현순 (차의과학대학교 약학대학) , 심미경 (차의과학대학교 약학대학)
Background: Innovative Alzheimer's disease drugs received approval in the United States in 2021 and 2023. This study aims to assess the safety and efficacy of these novel treatments, elucidate their mechanisms of action, and compare their impact on cognitive function improvement with approved drugs....
Van Duijn C. Alzheimer's disease, genetic and environmental?factors. Eur Psychiatry. 1998;13:217-8.
Service NHI. National health insurance corporation - alzheimer's?(f00 and g30) treatment statistics for the number of patients and total?treatment costs. Korea: Public Data Portal; 2022.
Tariot PN, Cummings JL, Katz IR, et al. A randomized,?double-blind, placebo-controlled study of the efficacy and safety of?donepezil in patients with alzheimer's disease in the nursing home?setting. J Am Geriatr Soc. 2001;49(12):1590-9.
Alzforum Foundation. Therapeutics: Tacrine. 2023. Available from: https://www.alzforum.org/therapeutics/tacrine. Accessed on Oct. 30,?2023.
FDA. Drugs@fda: Fda-approved drugs. 2021. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed on Oct.?30, 2023.
Kim J, Lee J, Jeong JH, Kang M, Bang JS. Study of the drugs?prescribed on alzheimer's disease: From the insurance claims data of?korea national health insurance service. Korean J Clin Pharm.?2014;24(4):255-64.
Huang L-K, Chao S-P, Hu C-J. Clinical trials of new drugs for?alzheimer disease. J Biomed Sci. 2020;27(1):1-13.
Korea Pharmaceutical Information Center. Kpic drug classification -?pharmaceutical information service 2021. Available from: https://www.health.kr/searchIngredient/KPICeffect.asp. Accessed on Oct.?30, 2023.
Zhu X-C, Tan L, Wang H-F, et al. Rate of early onset alzheimer's?disease: A systematic review and meta-analysis. Ann Transl Med.?2015;3(3):38.
Mejias-Trueba M, Perez-Moreno MA, Fernandez-Arche MA.?Systematic review of the efficacy of statins for the treatment of?alzheimer's disease. Clin Med. 2018;18(1):54.
Yu J-T, Xu W, Tan C-C, et al. Evidence-based prevention of?alzheimer's disease: Systematic review and meta-analysis of 243?observational prospective studies and 153 randomised controlled?trials. J Neurol Neurosurg Psychiatry. 2020;91(11):1201-9.
Cochrane. Chapter 8: Assessing risk of bias in a randomized trial?2022. Available from https://training.cochrane.org/handbook/archive/v6.3/chapter-08. Accessed December 21, 2023.
Cho, JH. Theory and Practice of Meta-Analysis. J Rhinol.?2020;27(2):83-9
Sperling R, Henley D, Aisen PS, et al. Findings of efficacy, safety,?and biomarker outcomes of atabecestat in preclinical alzheimer?disease: A truncated randomized phase 2b/3 clinical trial. JAMA?Neurol. 2021;78(3):293-301.
Cohen S, He P, Benea ML, et al. Item-level analysis of clinical?measures in patients with early symptomatic alzheimer's disease?following treatment with high-dose aducanumab in the phase 3?study emerge. Alzheimers Dement. 2021;17(S9):e057619.
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early?alzheimer's disease. N Engl J Med. 2021;384(18):1691-704.
Ostrowitzki S, Bittner T, Sink KM, et al. Evaluating the safety and?efficacy of crenezumab vs placebo in adults with early alzheimer?disease: Two phase 3 randomized placebo-controlled trials. JAMA?Neurol. 2022;79(11):1113-21.
Swanson C, Dhadda S, Hodgkinson M, et al. Lecanemab, an anti-Aβ Protofibril antibody: Updated data from a randomized, double-blind phase 2b proof of concept clinical trial and open-label?extension in early alzheimer's disease. J Neurol Sci. 2021;429:100.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early?alzheimer's disease. N Engl J Med. 2023;388(1):9-21.
Teng E, Manser PT, Pickthorn K, et al. Safety and efficacy of?semorinemab in individuals with prodromal to mild alzheimer?disease: A randomized clinical trial. JAMA Neurol. 2022;79(8):758-67.
Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized,?double-blind, placebo-controlled, parallel-group, phase 3 clinical?trial of sodium oligomannate for mild-to-moderate alzheimer's?dementia. Alzheimers Res Ther. 2021;13(1):62.
Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens?P. A phase 2 double-blind placebo-controlled 24-week treatment?clinical study of the p38 alpha kinase inhibitor neflamapimod in?mild alzheimer's disease. Alzheimers Res Ther. 2021;13(1):106.
Hirst WD, Stean TO, Rogers DC, et al. Sb-399885 is a potent,?selective 5-ht6 receptor antagonist with cognitive enhancing?properties in aged rat water maze and novel object recognition?models. Eur J Pharmacol. 2006;553(1-3):109-19.
Nirogi R, Jayarajan P, Abraham R, et al. Effects of masupirdine?(suvn-502) on agitation/aggression and psychosis in patients with?probable alzheimer's disease: A post hoc analysis. Alzheimers?Dement. 2022;18:e062695.
Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye?AM, Kaye AD. Aducanumab, a novel anti-amyloid monoclonal?antibody, for the treatment of alzheimer's disease: A comprehensive?review. Health Psychol Res. 2022;10(1):31925.
Breijyeh Z, Karaman R. Comprehensive review on alzheimer's?disease: Causes and treatment. Molecules. 2020;25(24):5789.
Hannestad J, Duclos T, Chao W, et al. Safety and tolerability of?grf6019 infusions in severe alzheimer's disease: A phase ii double-blind placebo-controlled trial. J Alzheimers Dis. 2021;81(4):1649-62.
Koh SH, Kwon HS, Choi SH, et al. Efficacy and safety of gv1001 in?patients with moderate-to-severe alzheimer's disease already?receiving donepezil: A phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res Ther. 2021;13(1):66.
Wang T, Kuang W, Chen W, et al. A phase ii randomized trial of?sodium oligomannate in alzheimer's dementia. Alzheimers Res?Ther. 2020;12(1):110.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.